The role of peroxiredoxin II in chemoresistance of breast cancer cells
Tieli Wang,1 Anthony Joseph Gomez Diaz,1 Yun Yen2 1Department of Chemistry and Biochemistry, California State University Dominguez Hills, Carson, CA, USA; 2Department of Clinical and Molecular Pharmacology, Beckman Research Institute of City of Hope National Medical Center, Duarte, CA, USA Abstrac...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fce47c0a37004c25abbce92930409636 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Tieli Wang,1 Anthony Joseph Gomez Diaz,1 Yun Yen2 1Department of Chemistry and Biochemistry, California State University Dominguez Hills, Carson, CA, USA; 2Department of Clinical and Molecular Pharmacology, Beckman Research Institute of City of Hope National Medical Center, Duarte, CA, USA Abstract: Peroxiredoxin (Prx)II belongs to a family of redox-active proteins that use redox-sensitive cysteine in the active site to reduce peroxides. PrxII is induced by various oxidative stimuli and plays an important protective role against oxidative radical damage by reactive oxygen species. PrxII expression levels are correlated with resistance to radiation therapy or certain anti-cancer drugs in radioresistant breast cancer cells, glioblastomas, and head and neck cancer cells as well as in tissue isolated from head and neck patients who do not respond to radiation therapy. Small interfering RNA (siRNA) that inhibits the PrxII gene expression has been shown to partially reverse the radioresistant phenotype in radiation resistant breast cancer cells and sensitizes glioma cells to oxidative stress, highlighting the potential clinical importance of PrxII in radiation resistance in cancer. This article focuses on the role that PrxII may play in chemoresistant breast cancer cells. Keywords: siRNA, redox, cysteine disulfide bridges, targeted therapy, reactive oxygen species |
|---|